Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START: CT1812 in Early Alzheimer's Disease
NCT05531656Phase 2Active, not recruiting
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zervimesine in Alzheimer's disease (AD), sponsored by Cognition Therapeutics, Inc.. Started Jun 2023; status: active, not recruiting.
02
Drugs
zervimesine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05531656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531656.